Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 13 12:43PM ET
55.79
Dollar change
-0.49
Percentage change
-0.87
%
IndexS&P 500 P/E- EPS (ttm)-3.60 Insider Own0.08% Shs Outstand2.03B Perf Week-6.05%
Market Cap113.15B Forward P/E7.90 EPS next Y7.06 Insider Trans0.07% Shs Float2.03B Perf Month-4.49%
Income-7258.00M PEG- EPS next Q1.47 Inst Own77.73% Short Float1.26% Perf Quarter11.60%
Sales47.44B P/S2.39 EPS this Y-87.95% Inst Trans0.47% Short Ratio2.31 Perf Half Y35.41%
Book/sh8.45 P/B6.60 EPS next Y680.04% ROA-7.85% Short Interest25.60M Perf Year7.58%
Cash/sh3.99 P/C13.98 EPS next 5Y-3.30% ROE-31.46% 52W Range39.35 - 61.08 Perf YTD8.73%
Dividend Est.2.39 (4.29%) P/FCF8.20 EPS past 5Y5.14% ROI-10.78% 52W High-8.66% Beta0.45
Dividend TTM2.40 (4.30%) Quick Ratio1.09 Sales past 5Y16.92% Gross Margin55.87% 52W Low41.78% ATR (14)1.31
Dividend Ex-DateJan 03, 2025 Current Ratio1.24 EPS Y/Y TTM-190.62% Oper. Margin17.62% RSI (14)41.95 Volatility2.01% 2.29%
Employees34100 Debt/Eq3.00 Sales Y/Y TTM5.56% Profit Margin-15.30% Recom2.64 Target Price59.89
Option/ShortYes / Yes LT Debt/Eq2.93 EPS Q/Q-36.16% Payout59.82% Rel Volume0.58 Prev Close56.28
Sales Surprise5.57% EPS Surprise20.47% Sales Q/Q8.44% EarningsOct 31 BMO Avg Volume11.09M Price55.79
SMA20-4.06% SMA500.07% SMA20013.61% Trades Volume3,335,200 Change-0.87%
Date Action Analyst Rating Change Price Target Change
Dec-10-24Resumed BofA Securities Neutral $63
Nov-15-24Initiated Wolfe Research Peer Perform
Nov-13-24Upgrade Daiwa Securities Neutral → Outperform
Nov-12-24Upgrade Leerink Partners Market Perform → Outperform $73
Oct-25-24Downgrade Citigroup Buy → Neutral $75 → $55
Oct-17-24Initiated Bernstein Mkt Perform $56
Jul-29-24Downgrade Barclays Overweight → Equal Weight $41
Mar-11-24Downgrade Societe Generale Buy → Hold
Feb-06-24Downgrade Redburn Atlantic Buy → Neutral $77 → $54
Jan-03-24Downgrade BofA Securities Buy → Neutral $68 → $60
Dec-11-24 04:17PM
Dec-09-24 05:45PM
Dec-07-24 05:30AM
Dec-03-24 08:00AM
Dec-02-24 07:44AM
06:59AM Loading…
Nov-26-24 06:59AM
Nov-22-24 04:09PM
11:30AM
Nov-19-24 06:59AM
Nov-18-24 07:30AM
12:41AM
Nov-15-24 07:22PM
08:23AM
06:59AM
Nov-13-24 04:07PM
04:05PM Loading…
Nov-12-24 04:05PM
07:00AM
Nov-11-24 07:00PM
04:32PM
04:04PM
03:45PM
10:12AM
09:39AM
06:59AM
Nov-08-24 09:34AM
Nov-05-24 05:00PM
Nov-01-24 03:07PM
Oct-31-24 04:16PM
04:12PM
02:43PM
10:03AM Loading…
10:03AM
07:12AM
06:59AM
Oct-29-24 11:17AM
Oct-28-24 06:59AM
Oct-26-24 07:00AM
Oct-16-24 04:21PM
Oct-15-24 06:09PM
Oct-14-24 09:59PM
Oct-07-24 05:30AM
Oct-03-24 05:35PM
01:11PM
Sep-30-24 07:00AM
Sep-27-24 07:38PM
04:18PM
02:17PM
11:58AM
11:06AM
11:00AM
09:44AM
09:36AM
06:59AM
05:59AM
Sep-26-24 09:05PM
07:20PM
Sep-25-24 08:29PM
Sep-18-24 06:59AM
Sep-16-24 05:25AM
Sep-15-24 08:55AM
Sep-12-24 06:59AM
Sep-10-24 05:45PM
Sep-09-24 06:59AM
Sep-08-24 02:30AM
Sep-06-24 07:00AM
Sep-01-24 03:33AM
Aug-28-24 06:19PM
Aug-27-24 06:59AM
Aug-26-24 06:59AM
Aug-21-24 06:59AM
Aug-19-24 06:59AM
Aug-16-24 07:30AM
Aug-15-24 05:30PM
03:48PM
12:34PM
10:49AM
07:49AM
Aug-08-24 06:30AM
Jul-29-24 06:30AM
Jul-27-24 11:31AM
Jul-26-24 07:06PM
01:26PM
11:33AM
10:36AM
08:55AM
06:59AM
04:57AM
Jul-25-24 06:03PM
Jul-19-24 06:59AM
Jul-11-24 02:23PM
Jul-10-24 12:00PM
Jul-09-24 07:40AM
Jul-08-24 06:59AM
06:43AM
Jul-05-24 06:45AM
Jun-30-24 10:13AM
Jun-27-24 01:14PM
Jun-23-24 01:38PM
Jun-21-24 07:30PM
06:59AM
Jun-20-24 06:59AM
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Holzer Phil MSVP and ControllerNov 04 '24Sale55.6270038,93011,760Nov 05 05:53 PM
BOERNER CHRISTOPHER S.Chief Executive OfficerNov 01 '24Option Exercise0.002,9640104,169Nov 05 05:42 PM
Hirawat SamitEVP,Chief Med.Offr.,Drug Dev.Nov 01 '24Buy54.671,830100,05562,109Nov 05 05:41 PM
Holzer Phil MOfficerNov 04 '24Proposed Sale55.6270038,930Nov 04 11:20 AM
Gallman CariEVP, Corporate AffairsOct 02 '24Option Exercise0.004,55806,667Oct 03 06:33 PM
Gallman CariEVP, Corporate AffairsAug 01 '24Option Exercise0.001,06102,493Aug 05 06:01 PM
Shanahan KarinEVP, Glob. Prod. Dev. & SupplyApr 01 '24Option Exercise0.003,30606,532Apr 02 06:45 PM
Lenkowsky AdamEVP, Chief Commercial OfficerMar 10 '24Option Exercise0.0015,016013,859Mar 12 09:54 PM
LEUNG SANDRAEVP, General CounselMar 10 '24Option Exercise0.0046,7840371,312Mar 12 09:43 PM
Plenge Robert MEVP, Chief Research OfficerMar 10 '24Option Exercise0.009,143015,182Mar 12 09:21 PM
Poole Ahn AmandaEVP, Chief Human ResourcesMar 10 '24Option Exercise0.005,45804,841Mar 12 09:11 PM
Hirawat SamitEVP,Chief Med.Offr.,Drug Dev.Mar 10 '24Option Exercise0.0038,388080,256Mar 12 08:40 PM
Holzer Phil MSVP and ControllerMar 10 '24Option Exercise0.005,520014,916Mar 12 08:31 PM
Hoch LynellePresident, Cell Therapy Org.Mar 10 '24Option Exercise0.004,35103,781Mar 12 08:01 PM
Gallman CariEVP, Corporate AffairsMar 10 '24Option Exercise0.002,76102,655Mar 12 08:00 PM
BOERNER CHRISTOPHER S.Chief Executive OfficerMar 10 '24Option Exercise0.0054,6380129,769Mar 12 07:58 PM
Elkins David VEVP, Chief Financial OfficerMar 10 '24Option Exercise0.0064,3260225,111Mar 12 05:43 PM
Caforio GiovanniExecutive Chair of the BoardMar 10 '24Option Exercise0.00190,1300529,662Mar 12 05:42 PM
Meyers Gregory ScottEVP, Chief Digital & Tech Off.Feb 01 '24Option Exercise0.002,54306,040Feb 05 07:10 PM